Granules India Q4 FY26 Revenue Up 23% YoY

Granules India reported Q4 FY26 revenue of INR14,706 million, a 23% YoY increase, and full-year revenue of INR53,656 million, up 20% YoY.
The company's peptide CDMO business, Ascelis, turned EBITDA positive in Q4 and contributed INR1,593 million in FY26 revenue.
Gross margin expanded to 65.7% in Q4, driven by a shift towards complex generics and the peptide CDMO business.
Net debt reduced to INR4,021 million, with net debt to EBITDA improving to 0.34x, supported by equity infusion and EBITDA growth.